Introduction
Iron deficiency is the most common micronutrient deficiency and the most common cause of anemia in childhood. 1 Iron is important for both growth and development of the infants. Ferropenic anemia caused by severe iron deficiency in infancy is associated with impaired health and serious neurological impairment, such as mental, motor, social, emotional, neurophysiological, and neurocognitive dysfunction. 2 In general, infants born at term with adequate birth weight have sufficient iron stores for the first 4e6 months of life, the recommended period of exclusive breastfeeding by the World Health Organization (WHO). 3 Breast feeding in this period reduces infant mortality that is caused by common childhood illnesses such as diarrhea and pneumonia, 4 and it also hastens children's recovery from illness. After age 6 months, as the children grow with concomitant expansion of blood volume, the body iron stores are depleted while body iron demand is increased; thus breast milk becomes insufficient for iron supply. Therefore, infants who are predominantly breastfed beyond age 6 months are potentially prone to have iron deficiency anemia (IDA) 5 ; the addition of sufficient complementary foods is essential for infant growth at this time.
Due to the enthusiastic advocacy of breastfeeding in our society, the population of breastfed infants is increasing. Therefore, IDA related to prolonged predominant breastfeeding should be of concern in infant care. The manifestation of IDA is always indistinguishable; therefore, its detection relies mostly on the alertness of physicians. In this retrospective study, 15 cases of IDA are collected; the manifestations, diagnostic process, and treatment responses are presented.
Methods
This is a retrospective chart review study. From January 2007 to December 2010, fifteen babies were analyzed at the age of 6e18 months; 10 were male and five female. The enrollment criteria was as follows: predominant breastfeeding beyond 6 months of age; presence of microcytic anemia [hemoglobin (Hb) <11 g/dL and mean corpuscular volume (MCV) <70 fL]; and confirmation of IDA through laboratory test or presence of adequate response to iron therapy. The laboratory criteria are ferritin <15 ng/mL, and adequate response to iron therapy is defined as increase in Hb level by 1 g/dL after 1 month of appropriate iron-replacement therapy. 6 Three were full-term babies, whose mean birth body weight was 3126 AE 692 g; and 12 were preterm babies (gestational age <37 weeks) including one pair of twins and a single twin, whose mean birth body weight was 1858 AE 417 g. Predominant breastfeeding was defined as scanty addition of complimentary food. None of the babies had gross bloody stools, hematuria, or other bleeding events.
The clinical presentation, age at diagnosis, initial Hb levels and MCV, growth percentile, and duration of treatment were recorded and analyzed. Table 1 shows the baseline characteristics and laboratory data of all patients. In nine cases, anemia was suspected by pediatricians owing to pallor; in four patients, anemia was detected on routine blood tests for other diseases such as fever, urinary tract infection, and respiratory tract infection. One patient had seizure, and pallor was noticed by the physician; another had pica, which was manifested as eating paper.
Results
Confirmation of IDA through complete laboratory checks such as ferritin/iron levels and total iron-binding capacity (TIBC) were available in eight cases only. The mean values in these patients were as follows: ferritin 9.2 ng/mL (range, 0.4e53.0 ng/mL; normal, <15 ng/mL); iron 15.6 mg/dL (range, 7e27 mg/dL; normal, 40e100 mg/dL); and TIBC 462 mg/dL (range, 378e606 mg/dL; normal, 100e400 mg/ dL). The only patient with normal ferritin level (53.0 ng/ mL) at diagnosis was a case of pneumonia. Her initial iron level was low (14 mg/dL) and TIBC was borderline (378 mg/ dL). She had normalization of both hemoglobin and MCV after iron therapy for 2 months; therefore, this case was enrolled. Excluding these extreme data, which might be a response to infection, the mean value of ferritin in this group was 2.97 ng/mL (range 0.4e6.34 ng/mL). In the remaining seven patients, IDA was confirmed through therapeutic response. After iron therapy for an average duration of 4 months (range, 2e6 months), their Hb increased from 8.15 g/dL to 11.6 g/dL; and their MCV increased from 58 fL to 75 fL. The therapeutic iron trial remains the most cost-effective strategy for the diagnosis of IDA in patients with mild microcytic anemia. 7 Hb electrophoresis and staining for Hb H inclusion bodies were performed to exclude thalassemia in eight patients who had positive family history; one patient had a-thalassemia, and another had b-thalassemia. For the case with athalassemia, the initial laboratory data were Hb 9.7 g/dL, MCV 69 fL, and Hb H stain positive; after 2 months of iron therapy, the Hb level was 12.1 g/dL, and MCV was 80 fL. Possibly, the baby had a-thalassemia trait, which is caused by the deletion of two a genes; MCV reduction in such cases may be borderline. The initial laboratory data in the patient with b-thalassemia were as follows: ferritin, 0.77 ng/ mL; iron, 27 mg/dL; TIBC, 399 mg/dL; Hb A, 87.4%; Hb A2, 6%; and Hb F, 6.6%. After 2 months of iron therapy with poor compliance, no definite response was elicited, and the patient was lost to follow-up.
The mean postnatal age at IDA diagnosis was 10.5 months: 9.0 months in the full-term babies, and 10.8 months in the preterm babies. The average initial Hb level was 8.0 g/dL (full-term group, 8.6 g/dL; preterm group, 7.9 g/dL), and the average initial MCV was 57.5 fL (fullterm group, 62.0 fL; preterm group, 56.4 fL). All babies received oral iron supplements (Ferrum Hausmann drops 50 mg/mL) at a dose of 4e6 mg/kg/day. The average duration of treatment was 3.6 months (range 2e6 months). After treatment, the average Hb level was 11.5 g/dL, and the average MCV was 73.9 fL (Table 1 ). All the babies, except for the case with b-thalassemia who was lost to follow-up, were free from neurological sequelae. Most of the patients had appropriate growth with parameters within the 3rde85th percentile in mode; three preterm cases had body height <3rd percentile and one also had body weight <3rd percentile. After iron therapy, there was no remarkable change in their growth status, possibly due to the short duration of observation.
Discussion
A variety of heterogeneous agents that possess antimicrobial activity are found in human milk. As a result, infants who are exclusively breastfed in the initial 4 months of life have fewer episodes of diarrhea, otitis media, pneumonia, bacteremia, and meningitis during the 1 st year of life in comparison with infants who are formula-fed. 8e10 In addition, breastfeeding facilitates the maternaleinfant relationship, and its psychological advantages are well recognized. Owing to its numerous beneficial effects on infant health, exclusive breastfeeding is recommended during the initial 4e6 months of life by WHO. 3 However, the iron content of human milk is low (0.2e0.4 mg/L); so iron depletion is a potential risk in infants who are predominantly or exclusively breastfed beyond age 6 months. Before this age, the better absorption of breast milk iron and the iron stores in most full-term babies may prevent iron deficiency. 11, 12 Calvo et al 5 reported that, at age 6 months, IDA was detected in 44.0% of the breastfed babies, but only in 14.3% of the formula-fed babies; at 9 months, the incidence was 27.8% and 7.1%, respectively. Preterm infants, who have smaller iron stores, more iatrogenic blood loss during the neonatal period, and faster growth rates thereafter, are at higher risk of developing IDA. 5 In this study, 80% of the cases were preterm babies, whose initial Hb levels and MCV were lower than the term babies (Hb, 7.9 g/dL vs. 8.6 g/dL; MCV, 56.4 fL vs. 62.0 fL). Other risk factors for IDA include maternal anemia, previous blood loss, low birth weight, and being fed cow's milk instead of breast or formula milk before the age of 1 year.
13e15
A survey conducted in Taiwan showed that 45.6% of 6-month-old babies were exclusively breastfed in 2011. 16 Physicians should be vigilant for the possibility of IDA in these babies. To prevent IDA, breastfed infants should receive iron supplementation in the form of complementary infant foods such as iron-fortified cereals, red meat, or egg after age 6 months; and they should be offered ironfortified infant formula after weaning breast milk. Both the WHO 3 and the Taiwan Pediatric Association 17 emphasize the addition of iron-fortified and zinc-fortified foods for breastfed infants after age 4e6 months.
The treatment of IDA includes dietary changes as well as iron administration. Under good compliance to therapy, the increase in Hb by 1 g/dL after 4 weeks of iron supplementation can confirm the diagnosis of IDA. 6 The potential causes of failure of response include incompliance with therapy and coexistence of other diseases such as a-and bthalassemia, which affect approximately 6e8% and 1e2% of the Taiwanese population, respectively. 18 In this study, all babies except for the one with b-thalassemia showed a good response to iron therapy; the initial presentation, including pallor, seizure, or pica, resolved with an increase in Hb and MCV. Oral iron supplementation is recommended for an additional 2 months after Hb levels return to the normal range for the child's age 10 ; however, most patients Dx Z diagnosis; GA Z gestational age; Hb Z hemoglobin; MCV Z mean corpuscular volume; SD Z standard deviation; Tx Z treatment.
in this study did not complete the full course. The healthy appearance of these patients may make the caregivers feel complacent and lead to premature cessation of iron supplementation. Physicians should take greater responsibility in advocating complete treatment.
Because this was a retrospective case-collection study, we could not determine the true prevalence of IDA in infants or compare breastfed and formula-fed babies. Because the manifestations of IDA are subtle, both the caregivers and the pediatricians may miss the detection or be loose in compliance with therapy. Our study is to reemphasize the importance of this historic disease. Education of adding iron-fortified supplement food at 4e6 months old should be included in the advocacy of breastfeeding to decrease the occurrence of IDA in infants.
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